Promising Outlook for ArriVent BioPharma: Buy Rating Justified by Upcoming EGFR PACC Mutant NSCLC Program Updates

Analyst Soumit Roy from JonesTrading maintained a Buy rating on ArriVent BioPharma, Inc. (AVBP – Research Report) and keeping the price target at $40.00.

Soumit Roy’s rating is based on the anticipation of significant upcoming updates from ArriVent BioPharma, Inc. regarding their EGFR PACC mutant NSCLC program. The company is expected to release longer-term Phase 1b follow-up data, focusing on progression-free survival (PFS) and long-term safety outcomes, which could potentially surpass the current benchmark of a median PFS of over 10 months. Additionally, the alignment with the FDA on the pivotal trial design is a crucial step forward, indicating a clear regulatory path.
Furthermore, the safety profile of ArriVent’s treatment, firmo, offers an advantage over existing therapies like Gilotrif, particularly for patients with specific atypical EGFR mutations. If firmo demonstrates efficacy across a broader range of mutations than current treatments, it could lower the approval threshold and enhance its market position. These factors combined suggest a promising outlook for ArriVent, justifying the Buy rating.

In another report released on May 15, Guggenheim also maintained a Buy rating on the stock with a $45.00 price target.